Eli Lilly and Company
Global pharmaceutical company developing life-changing medicines in diabetes, oncology, immunology, and neuroscience
What the page says before deeper research
Quality, growth, value, ownership, risk, and source confidence.
Moat 95/100, high switching costs, 118% NRR.
Growth appears healthy from +47% YoY revenue growth.
Forward P/E of 24.9x versus +47% growth gives a 0.5x multiple-to-growth read.
No SEC-backed 13F layer is matched yet, so ownership confirmation is unavailable.
Retention and AI disruption risks are low; valuation is not flagged expensive.
Fundamentals from finnhub as of 2026-05-17; ownership confirmation is not available here.
This is the cleanest available operating signal in the provided data and helps frame whether the business is still expanding rapidly.
Beginner valuation check
Data pending from FMP or Finnhub.
Positive price performance shows recent market sentiment, not a full investment thesis.
Forward P/E around 24.9x means investors pay about $24.9 for each expected $1 of future profit per share, usually the next 12 months or next fiscal year. It is a forecast, not a fact.
A P/E around 37.4x means investors pay about $37.4 for each $1 the company earned per share over the last 12 months, usually the last four quarterly reports.
Source: market data index. As of May 21, 2026. P/E can be unavailable or misleading when earnings are negative.
Beginner guide
Eli Lilly makes medicines that help people with diabetes, weight loss, and brain diseases. Their medicines are some of the most important in the world right now.
Global pharmaceutical company developing life-changing medicines in diabetes, oncology, immunology, and neuroscience
Eli Lilly and Company makes money through Diabetes & Obesity (~55% of revenue), Oncology (~15% of revenue), Neuroscience (~10% of revenue), and Immunology (~10% of revenue).
20+ year drug development cycles create massive switching costs - changing systems mid-trial risks $2B+ investment
Eli Lilly and Company can disappoint if execution, competition, valuation, or demand cycles weaken growth, margins, customer retention, or investor confidence.
Eli Lilly and Company is like part of the healthcare toolkit: patients, providers, or researchers rely on it when quality and trust matter.
You are basically betting that Eli Lilly and Company can keep turning diabetes & obesity into durable value while managing execution, competition, valuation, or demand cycles.
A 0-100 shortcut for how defensible the business looks in this company brief. Eli Lilly and Company is scored at 95.
How painful it is for customers to leave. this company brief rates Eli Lilly and Company as high.
Whether existing customers tend to spend more or less over time. The company brief model uses 118%.
The main pieces of the company here are Diabetes & Obesity, Oncology, Neuroscience, and Immunology.
Price divided by earnings. It is a quick valuation check, but it can mislead when earnings are temporarily high, low, or negative.
A quarterly filing that shows what many large institutional investors owned at quarter end.
The first four questions
Lilly’s diabetes & obesity franchise is the main operating engine here, and its scale plus long drug-development cycles create high switching costs that can support durable growth if execution stays strong.
LLY can disappoint if execution, competition, valuation, or demand cycles weaken growth, investor confidence, or demand across its core diabetes & obesity franchise.
Diabetes & Obesity
Next earnings date unavailable from configured sources.
Bull / Neutral / Bear
Investors continue to focus on Lilly’s diabetes & obesity scale and the market applies a forward multiple that reflects both quality and high expectations.
Forward P/E around 24.9x stays aligned with continued business momentum.
The diabetes & obesity franchise keeps expanding and Lilly continues turning that operating strength into durable value while protecting its lead in a highly regulated market.
Revenue growth remains strong around +47% or improves while the core franchise stays the main growth engine.
Investors continue to focus on Lilly’s diabetes & obesity scale and the market applies a forward multiple that reflects both quality and high expectations.
Forward P/E around 24.9x stays aligned with continued business momentum.
If execution slows, competition intensifies, or demand cycles weaken, the market may reprice the story even if the long-term franchise remains intact.
Revenue growth cools, competition increases, or valuation becomes harder to justify.
Beginner checklist
Needs earnings calendar data from a provider.
This is the cleanest available operating signal in the provided data and helps frame whether the business is still expanding rapidly.
Margin trend needs company financial statement data; do not infer it from price movement.
This is the current valuation anchor, but it should be read alongside growth in Lilly’s core diabetes and obesity franchise.
No SEC-backed ownership rows are available for this ticker yet.
Needs insider transaction data from a provider.
For Lilly, this is the operating area to watch first because it is the largest revenue line and the clearest business-driver signal in the provided data.
Eli Lilly and Company is exposure to healthcare operating model with high switching costs and 118% net revenue retention.
20+ year drug development cycles create massive switching costs - changing systems mid-trial risks $2B+ investment
The main question is whether the company can keep customer value compounding without margin pressure eroding the moat.
Pro access unlocks the workflow simulator for this company brief.
Simulator coverage pending
This ticker has a company brief, but richer workflow modules have not been built yet.
No SEC-backed 13F rows are matched for this ticker yet. We do not fabricate ownership rows.
- 20+ year drug development cycles create massive switching costs - changing systems mid-trial risks $2B+ investment
- FDA-validated systems with 21 CFR Part 11 compliance create regulatory lock-in impossible to replicate
- Integrated clinical-regulatory-commercial workflows span entire 15-year product lifecycle
- AI enhances rather than replaces core regulatory expertise and relationship management
- Network effects: more KOL relationships = better clinical insights = faster approvals = more resources for R&D